Arvinas (ARVN) stock price is $7.57, down 1.17% on the day, as of Oct 21, 2026. It has a market cap of $490.54Mn and a P/E ratio of 52.75, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap490.54 Mn
P/E52.75
P/S1.55
Div. Yield0.00
Total Debt (Qtr)300,000.00
Revenue Growth (1y) (Qtr)1,014.73
Add ratio to table…
About
Arvinas, Inc. is a clinical-stage biotechnology company focused on developing therapeutics using its proprietary PROteolysis TArgeting Chimera or PROTAC platform to degrade disease causing proteins. The company designs small molecule compounds that recruit an E3 ubiquitin ligase to a target protein, forming a ternary complex that leads to ubiquitination and proteasomal degradation. This approach differs from traditional inhibition because it removes the protein entirely…
Arvinas, Inc. is a clinical-stage biotechnology company focused on developing therapeutics using its proprietary PROteolysis TArgeting Chimera or PROTAC platform to degrade disease causing proteins. The company designs small molecule compounds that recruit an E3 ubiquitin ligase to a target protein, forming a ternary complex that leads to ubiquitination and proteasomal degradation. This approach differs from traditional inhibition because it removes the protein entirely rather than blocking its activity. Arvinas, Inc. aims to treat serious illnesses such as cancer and neurodegenerative disorders by eliminating pathogenic proteins that drive disease. Its pipeline includes multiple candidates targeting proteins like estrogen receptor, KRAS G12D, BCL6, LRRK2 and the androgen receptor. The company leverages its drug discovery engine to create small molecule degraders that can engage the cell's natural ubiquitin proteasome system and potentially offer oral dosing and broad tissue distribution.
Arvinas, Inc. generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical firms. In July 2021 the company received an upfront payment of $650 million from Pfizer for the co development and co commercialization of vepdegestrant, with potential milestone payments reaching up to $1.4 billion. In April 2024 Arvinas, Inc. entered into a transaction with Novartis that included an upfront payment of $150 million and the right to receive up to $1.01 billion in milestones, of which $20 million was recognized during 2025. Additionally the company earned $28 million from an earlier research collaboration with Pfizer and is eligible for further milestone and royalty payments under various agreements. As of the filing date Arvinas, Inc. has not yet commercialized any product, so its revenue consists of these upfront, milestone and potential royalty payments. The company also retains rights to receive tiered royalties on net sales of licensed products should any of its candidates reach the market.
Arvinas, Inc. occupies a pioneering position in the emerging field of targeted protein degradation, a modality that seeks to eliminate disease causing proteins through the cell's ubiquitin system. The company faces competition from other biotech firms pursuing similar approaches, including C4 Therapeutics, Kymera Therapeutics, Nurix Therapeutics and others that develop degraders or molecular glues. Arvinas, Inc. differentiates itself with a proprietary PROTAC discovery engine that enables the design of degraders capable of targeting traditionally undruggable proteins such as transcription factors and scaffolding molecules. Its platform also offers potential advantages like oral bioavailability, catalytic activity and the ability to spare healthy proteins while degrading disease associated variants. Notably Arvinas, Inc. was the first to submit a new drug application for a PROTAC based therapy, underscoring its innovative edge in the field.
Arvinas, Inc. ultimately serves patients suffering from oncology and neurology conditions who may benefit from its investigational therapies. In oncology the company focuses on patients with estrogen receptor positive HER2 negative breast cancer, non small cell lung cancer, colorectal cancer and pancreatic cancer harboring specific mutations such as KRAS G12D. In neurology the company targets individuals with Parkinson's disease, progressive supranuclear palsy and other neurodegenerative disorders linked to proteins like LRRK2. In hematology Arvinas, Inc. develops agents for relapsed or refractory non Hodgkin lymphoma by targeting the BCL6 transcription factor. Additionally the company works on treatments for spinal bulbar muscular atrophy by addressing the mutant androgen receptor in skeletal muscle. In the near term the company's customers are its collaborative partners, namely Pfizer with whom it co develops vepdegestrant, Novartis which holds the rights to luxdegalutamide and Genentech with which it has explored multiple target programs. These partnerships provide the near term revenue stream while the long term goal is to deliver medicines directly to patients and healthcare providers.
Sector:HealthcareSector rationaleArvinas is a clinical-stage biotechnology company that designs and develops therapeutics for cancer and neurodegenerative disorders using its PROTAC platform. Its revenue is derived from collaboration and licensing agreements with pharmaceutical firms like Pfizer and Novartis for the development of medical treatments.Industry:BiotechnologyBiotechnologyPrimaryArvinas is a clinical-stage biotechnology company that develops therapies using its proprietary PROTAC platform to degrade disease-causing proteins. Its revenue is derived from collaboration and licensing agreements with partners like Pfizer and Novartis, including upfront payments and milestones.Classified using BQ-MICSCIK: 0001655759
Bull & bear
Investment Thesis
▲ Bull case
Arvinas has successfully de-risked its near-term valuation with the FDA approval of Vepdegestrant in collaboration with Pfizer, a pivotal milestone that validates its PROTAC platform in a regulated commercial setting and unlocks immediate revenue potential through royalty streams and milestone payments, which were not fully appreciated in the current market valuation given the company's depressed market cap relative to its cash balance and pipeline breadth. The approval represents the first-ever FDA-sanctioned PROTAC degrader, establishing a historic precedent that could attract strategic interest from larger pharmaceutical companies seeking to leverage Arvinas' platform for other high-value targets, particularly as the company has indicated ongoing discussions for third-party commercialization partnerships that could be finalized well before the June 5 PDUFA date, providing near-term non-dilutive funding to extend its cash runway beyond the stated 2028 horizon. This regulatory validation significantly reduces the binary risk traditionally associated with early-stage biotechs and provides a concrete foundation for re-rating the stock based on tangible, near-term cash flow visibility rather than solely on speculative pipeline progress.
The company's strategic refocusing on four core Phase 1 programs—ARV-102 (LRRK2), ARV-806 (KRAS G12D), ARV-393 (BCL6), and ARV-027 (polyQ AR)—creates a concentrated, high-conviction portfolio where near-term clinical readouts could serve as powerful catalysts for investor confidence, especially as management has explicitly tied go/no-go decisions to demonstrable differentiation in safety, efficacy, or mechanism versus existing therapies, a framework that increases the likelihood of efficient capital allocation and reduces the risk of prolonged investment in non-differentiating assets. The upcoming data readouts for ARV-102 at the Alzheimer’s and Parkinson’s Diseases Conference and ARV-806 in the coming months are particularly significant because they target indications with high unmet need and limited competition—Parkinson’s disease and KRAS G12D-mutant cancers—where even modest efficacy signals could be viewed as transformative given the lack of approved disease-modifying therapies, and the company’s emphasis on biomarker engagement (e.g., >50% LRRK2 degradation in CSF) provides a measurable, objective threshold for success that is less susceptible to subjective interpretation than traditional clinical endpoints.
Arvinas’ preclinical advancements in ARV-6723 (HPK1 degrader) and its pan-KRAS program represent underappreciated long-term options that could significantly extend the company’s growth trajectory beyond the immediate 2026–2028 window, as the HPK1 program addresses a fundamental limitation of current immuno-oncology therapies by targeting both kinase and scaffolding functions to overcome resistance mechanisms, with preclinical data showing superior tumor growth control compared to monotherapies and combinations with anti–PD-1, while the pan-KRAS initiative leverages the company’s expertise to target a broad spectrum of KRAS-driven malignancies—including wild-type and mutant variants—offering a potential solution to the pervasive problem of RAS pathway redundancy that has limited the durability of current KRAS inhibitors, and both programs are progressing toward IND-enabling studies in 2026, suggesting that Arvinas is building a deep, layered pipeline that could sustain value creation even if individual programs face setbacks, thereby reducing the portfolio’s reliance on any single asset for long-term success.
Arvinas has successfully de-risked its near-term valuation with the FDA approval of Vepdegestrant in collaboration with Pfizer, a pivotal milestone that validates its PROTAC platform in a regulated commercial setting and unlocks immediate revenue potential through royalty streams and milestone payments, which were not fully appreciated in the current market valuation given the company's depressed market cap relative to its cash balance and pipeline breadth. The approval represents the first-ever FDA-sanctioned PROTAC degrader, establishing a historic precedent that could attract strategic interest from larger pharmaceutical companies seeking to leverage Arvinas' platform for other high-value targets, particularly as the company has indicated ongoing discussions for third-party commercialization partnerships that could be finalized well before the June 5 PDUFA date, providing near-term non-dilutive funding to extend its cash runway beyond the stated 2028 horizon. This regulatory validation significantly reduces the binary risk traditionally associated with early-stage biotechs and provides a concrete foundation for re-rating the stock based on tangible, near-term cash flow visibility rather than solely on speculative pipeline progress.
The company's strategic refocusing on four core Phase 1 programs—ARV-102 (LRRK2), ARV-806 (KRAS G12D), ARV-393 (BCL6), and ARV-027 (polyQ AR)—creates a concentrated, high-conviction portfolio where near-term clinical readouts could serve as powerful catalysts for investor confidence, especially as management has explicitly tied go/no-go decisions to demonstrable differentiation in safety, efficacy, or mechanism versus existing therapies, a framework that increases the likelihood of efficient capital allocation and reduces the risk of prolonged investment in non-differentiating assets. The upcoming data readouts for ARV-102 at the Alzheimer’s and Parkinson’s Diseases Conference and ARV-806 in the coming months are particularly significant because they target indications with high unmet need and limited competition—Parkinson’s disease and KRAS G12D-mutant cancers—where even modest efficacy signals could be viewed as transformative given the lack of approved disease-modifying therapies, and the company’s emphasis on biomarker engagement (e.g., >50% LRRK2 degradation in CSF) provides a measurable, objective threshold for success that is less susceptible to subjective interpretation than traditional clinical endpoints.
Arvinas’ preclinical advancements in ARV-6723 (HPK1 degrader) and its pan-KRAS program represent underappreciated long-term options that could significantly extend the company’s growth trajectory beyond the immediate 2026–2028 window, as the HPK1 program addresses a fundamental limitation of current immuno-oncology therapies by targeting both kinase and scaffolding functions to overcome resistance mechanisms, with preclinical data showing superior tumor growth control compared to monotherapies and combinations with anti–PD-1, while the pan-KRAS initiative leverages the company’s expertise to target a broad spectrum of KRAS-driven malignancies—including wild-type and mutant variants—offering a potential solution to the pervasive problem of RAS pathway redundancy that has limited the durability of current KRAS inhibitors, and both programs are progressing toward IND-enabling studies in 2026, suggesting that Arvinas is building a deep, layered pipeline that could sustain value creation even if individual programs face setbacks, thereby reducing the portfolio’s reliance on any single asset for long-term success.
Despite the FDA approval of Vepdegestrant, Arvinas faces significant near-term financial pressure due to the precipitous decline in royalty revenue following the cessation of the Novartis license agreement, which drove the year-over-year drop in Q4 revenue from $59.2 million to $9.5 million and reduced annual revenue by only $0.8 million despite the new product launch, indicating that Vepdegestrant’s initial commercial uptake may be substantially slower than anticipated or that the economic terms of the Pfizer collaboration are less favorable than historical deals, and with cash reserves now just above $85 million—down from over $1 billion at the end of 2024—the company’s reliance on achieving multiple successful clinical readouts in 2026 to justify its valuation becomes increasingly tenuous, especially given that the stated cash runway into 2028 assumes no further setbacks in clinical timelines or unexpected increases in R&D spending, which could be challenged if any of the Phase 1 programs require dose escalation, additional cohorts, or unexpected toxicity monitoring that would increase costs beyond current projections.
The company’s emphasis on demonstrating differentiation through biomarker engagement—such as >50% LRRK2 degradation in CSF for ARV-102 or target depletion in preclinical models—carries substantial risk of misalignment with clinical efficacy, as there is no guarantee that biochemical target engagement will translate to meaningful clinical benefit in complex diseases like Parkinson’s or PSP, where past failures of biologics and small molecules targeting similar pathways have shown that target modulation does not equate to disease modification, and the lack of validated surrogate endpoints for early-phase trials in neurodegeneration and oncology means that investors may be interpreting promising biomarker data as predictive of clinical success when, in fact, the path from target degradation to functional improvement remains unproven in humans, creating a potential disconnect between scientific optimism and actual therapeutic value that could lead to premature enthusiasm followed by disappointing clinical outcomes.
Arvinas operates in highly competitive and well-funded therapeutic areas where incumbent players and well-capitalized biotechs are advancing similar modalities—including alternative degraders, bispecific antibodies, and next-generation inhibitors—with deeper clinical data and more established safety profiles, as evidenced by the crowded KRAS G12D landscape referenced in the Q&A where management acknowledged needing to surpass ~35% response rates to be considered differentiated, a bar that may be difficult to clear given the potency and specificity challenges inherent in PROTACs, and the company’s strategy of pursuing multiple early-stage programs simultaneously spreads limited managerial and financial resources thin, increasing the likelihood that none of the assets receive sufficient investment to reach pivotal inflection points, particularly as the company has deferred investment in later-stage assets like Vepdegestrant’s broader development in favor of early-phase exploration, which could result in a pipeline rich in preclinical promise but lacking in near-term de-risked, later-stage assets capable of generating sustainable revenue independent of partner-dependent milestones.
Despite the FDA approval of Vepdegestrant, Arvinas faces significant near-term financial pressure due to the precipitous decline in royalty revenue following the cessation of the Novartis license agreement, which drove the year-over-year drop in Q4 revenue from $59.2 million to $9.5 million and reduced annual revenue by only $0.8 million despite the new product launch, indicating that Vepdegestrant’s initial commercial uptake may be substantially slower than anticipated or that the economic terms of the Pfizer collaboration are less favorable than historical deals, and with cash reserves now just above $85 million—down from over $1 billion at the end of 2024—the company’s reliance on achieving multiple successful clinical readouts in 2026 to justify its valuation becomes increasingly tenuous, especially given that the stated cash runway into 2028 assumes no further setbacks in clinical timelines or unexpected increases in R&D spending, which could be challenged if any of the Phase 1 programs require dose escalation, additional cohorts, or unexpected toxicity monitoring that would increase costs beyond current projections.
The company’s emphasis on demonstrating differentiation through biomarker engagement—such as >50% LRRK2 degradation in CSF for ARV-102 or target depletion in preclinical models—carries substantial risk of misalignment with clinical efficacy, as there is no guarantee that biochemical target engagement will translate to meaningful clinical benefit in complex diseases like Parkinson’s or PSP, where past failures of biologics and small molecules targeting similar pathways have shown that target modulation does not equate to disease modification, and the lack of validated surrogate endpoints for early-phase trials in neurodegeneration and oncology means that investors may be interpreting promising biomarker data as predictive of clinical success when, in fact, the path from target degradation to functional improvement remains unproven in humans, creating a potential disconnect between scientific optimism and actual therapeutic value that could lead to premature enthusiasm followed by disappointing clinical outcomes.
Arvinas operates in highly competitive and well-funded therapeutic areas where incumbent players and well-capitalized biotechs are advancing similar modalities—including alternative degraders, bispecific antibodies, and next-generation inhibitors—with deeper clinical data and more established safety profiles, as evidenced by the crowded KRAS G12D landscape referenced in the Q&A where management acknowledged needing to surpass ~35% response rates to be considered differentiated, a bar that may be difficult to clear given the potency and specificity challenges inherent in PROTACs, and the company’s strategy of pursuing multiple early-stage programs simultaneously spreads limited managerial and financial resources thin, increasing the likelihood that none of the assets receive sufficient investment to reach pivotal inflection points, particularly as the company has deferred investment in later-stage assets like Vepdegestrant’s broader development in favor of early-phase exploration, which could result in a pipeline rich in preclinical promise but lacking in near-term de-risked, later-stage assets capable of generating sustainable revenue independent of partner-dependent milestones.